An experimental psychedelic therapy from the U.K. company Beckley Psytech significantly reduced symptoms of ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

Compared with placebo, pramipexole added to antidepressants reduces symptoms significantly at 12 weeks in treatment-resistant depression, a trial finds.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the therapy.

Introduction Major depressive disorder (MDD) is a major global healthcare challenge. This is, in part, due to the lack of treatment response and chronic course of MDD. Such a course of illness is ...

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

Shares of ATAI Life Sciences (NASDAQ:ATAI) skyrocketed 29% on Tuesday after the biotech company and its partner, Beckley ...

Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of a planned merger with mental health-focused company Atai Life ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe ...